Teva, Others Seek Changes to ‘Backward’ Generic Drug Bill

Generic drug companies actively trying to get their products on shelves want senators to update language in a sweeping health-care bill meant to dissuade companies from squatting on patents to block competition.

The BLOCKING Act would strip generic drugmakers of exclusivity rights if they fail to get their generic drug approved under certain circumstances, like within 30 months of first submitting an application to develop the generic, among other things. The measure is included as part of the broader Lower Health Care Costs Act (S.1895).

The proposal is meant to address the issue of “parking,” when a generic company ...